Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Raburn M. Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert, Heather McFall, Michelle Robinson, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Bin Zhou, Gordon Chau, Andreana Robertson, Sonia Maciejewski, Holly Hammond, Lauren Baracco, James Logue, Matthew B. Frieman, Gale Smith, Nita Patel, Gregory M. Glenn, Mark Adams, Mark Arya, Eugene Athan, Ira Berger, Paul A. Bradley, Toby Briskin, Richard Glover, Paul Griffin, Joshua Kim, Scott Kitchener, Terry Klein, Amber Leah, Indika Leelasena, Charlotte Lemech, Jason D. Lickliter, Mary Beth Manning, Fiona Napier-Flood, Paul Nugent, Susan Thackwray, Mark Turner